Journal of Neurology

, Volume 261, Issue 6, pp 1069–1072

Intravenous tenecteplase in acute ischemic stroke: an updated review


DOI: 10.1007/s00415-013-7102-0

Cite this article as:
Behrouz, R. J Neurol (2014) 261: 1069. doi:10.1007/s00415-013-7102-0


Tenecteplase in a genetically engineered variant of alteplase. Although the two have the same mechanism of action, tenecteplase has properties that makes it a seemingly more advantageous thrombolytic. Because of its rapid single-bolus administration, its use is favored over alteplase in the treatment of acute myocardial infarction. Over the past few years, several clinical studies have been conducted to assess the safety, feasibility, and efficacy of tenecteplase in ischemic stroke. In spite of the mixed results of these studies, experimentation with tenecteplase continues in from of clinical trials. In this article, the utility of tenecteplase in ischemic stroke will be discussed.


Stroke Cerebrovascular disease Tenecteplase Alteplase Tissue plasminogen activator Thrombolytics Thrombolysis Pharmacology 

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Division of Cerebrovascular Diseases and Neurological Critical Care, Department of NeurologyThe Ohio State University College of MedicineColumbusUSA

Personalised recommendations